Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
AssigneeSyntaxin Limited
InventorsJohn Andrew Chaddock, Philip Marks, Michael John Duggan
Life of this patent
Estimating the term…
Loading patent…
AssigneeSyntaxin Limited
InventorsJohn Andrew Chaddock, Philip Marks, Michael John Duggan
Estimating the term…
A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.
An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising:
An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising:
An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising:
An agent for the treatment of pain, wherein the agent has been obtained in the form of a fusion protein by a method comprising expressing in a host cell a genetic construct that codes for the agent, said agent comprising:
Dependencies are inferred from the claim text.